The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realitiesDoherty, Meg; Ford, Nathan; Vitoria, Marco; Weiler, Gundo; Hirnschall, GottfriedCurrent Opinion in HIV & AIDS: November 2013 - Volume 8 - Issue 6 - p 528–534 doi: 10.1097/COH.0000000000000008 TREATMENT OPTIMISATION: Edited by David H. Brown Ripin, Charles W. Flexner and Ben Plumley Abstract Author Information Purpose of review: The review summarizes the key new recommendations of the WHO 2013 guidelines for antiretroviral therapy and describes the potential impact of these recommendations on the HIV epidemic. Recent findings: The 2013 WHO guidelines recommend earlier initiation of antiretroviral therapy (ART) at CD4 500 cells/μl or less for all adults and children above 5 years. Further recommendations include initiation of ART irrespective of CD4 cell count or clinical stage for people co-infected with active tuberculosis disease or hepatitis B virus with severe liver disease, pregnant women, people in serodiscordant partnerships, and children under 5 years of age. The ART regimen comprising a once daily fixed-dose combination of tenofovir + lamivudine (or emtricitabine) + efavirenz is recommended as the preferred first-line therapy. Several approaches are also recommended to reach more people and increase health service capacity, including community and self-testing, and task shifting, decentralization, and integration of ART care. Summary: If fully implemented, the 2013 WHO ART guidelines could avert at least an additional 3 million deaths and prevent close to an additional 3.5 million new infections between 2012 and 2025 in low- and middle-income countries, compared with previous treatment guidelines. HIV Department, World Health Organization, Geneva, Switzerland Correspondence to Meg Doherty, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. Tel: +41 22 791 19 49; fax: +41 22 791 21 11; e-mail: firstname.lastname@example.org © 2013 Lippincott Williams & Wilkins, Inc.